Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19

There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kow, Chia Siang, Zaidi, Syed Tabish Razi, Hasan, Syed Shahzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152511/
https://www.ncbi.nlm.nih.gov/pubmed/32281055
http://dx.doi.org/10.1007/s40256-020-00406-0
_version_ 1783521494912991232
author Kow, Chia Siang
Zaidi, Syed Tabish Razi
Hasan, Syed Shahzad
author_facet Kow, Chia Siang
Zaidi, Syed Tabish Razi
Hasan, Syed Shahzad
author_sort Kow, Chia Siang
collection PubMed
description There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19.
format Online
Article
Text
id pubmed-7152511
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-71525112020-04-13 Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19 Kow, Chia Siang Zaidi, Syed Tabish Razi Hasan, Syed Shahzad Am J Cardiovasc Drugs Current Opinion There is ongoing debate on the safety of renin-angiotensin system (RAS) inhibitors in COVID-19. Recently published studies highlight a potential relationship between cardiovascular disease (CVD) and COVID-19. This article aims to summarize the evidence on the use of RAS inhibitors in CVD patients with COVID-19, focusing on safety issues of the RAS inhibitors and their relationship with COVID-19. Springer International Publishing 2020-04-13 2020 /pmc/articles/PMC7152511/ /pubmed/32281055 http://dx.doi.org/10.1007/s40256-020-00406-0 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Current Opinion
Kow, Chia Siang
Zaidi, Syed Tabish Razi
Hasan, Syed Shahzad
Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
title Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
title_full Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
title_fullStr Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
title_full_unstemmed Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
title_short Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
title_sort cardiovascular disease and use of renin-angiotensin system inhibitors in covid-19
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152511/
https://www.ncbi.nlm.nih.gov/pubmed/32281055
http://dx.doi.org/10.1007/s40256-020-00406-0
work_keys_str_mv AT kowchiasiang cardiovasculardiseaseanduseofreninangiotensinsysteminhibitorsincovid19
AT zaidisyedtabishrazi cardiovasculardiseaseanduseofreninangiotensinsysteminhibitorsincovid19
AT hasansyedshahzad cardiovasculardiseaseanduseofreninangiotensinsysteminhibitorsincovid19

Ejemplares similares